Hippocampal monoamine changes in the Flinders sensitive line rat: A case for the possible use of selective α-AR-antagonists in stress and anxiety disorders in companion animals.

Journal: Research in veterinary science

Volume: 135

Issue: 

Year of Publication: 2021

Affiliated Institutions:  Division of Pharmacology, Center of Excellence for Pharmaceutical Sciences, North-West University (Potchefstroom Campus), Potchefstroom, South Africa; South African MRC Unit on Risk and Resilience in Mental Disorders, Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Electronic address: brian.harvey@nwu.ac.za. Division of Pharmacology, Center of Excellence for Pharmaceutical Sciences, North-West University (Potchefstroom Campus), Potchefstroom, South Africa. Orion Pharma, Orion Corporation, Nottingham, United Kingdom. Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa. Centre for Veterinary Wildlife Studies and Department of Paraclinical Sciences, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.

Abstract summary 

Non-selective α-adrenoreceptor (AR) stimulation delivers favourable sedative, analgesic, muscle relaxant and anxiolytic actions in companion animals, but is associated with cardiovascular and respiratory side effects. Anxiety conditions underscore monoamine disturbances amenable to α-AR modulation. We investigated sub-chronic (14 day s.c.) treatment with the selective α-AR antagonist, ORM-10921 (0.03, 0.1, 0.3 mg/kg/d) on hippocampal noradrenaline (NA), dopamine (DA), serotonin (5-HT) and their turnover levels in stress sensitive Flinders Sensitive Line (FSL) rats versus Flinders Resistant Line (FRL) controls, using high performance liquid chromatography. The effects of ORM-10921 were compared to the non-selective α-AR antagonist, idazoxan (IDAZ; 3 mg/kg/d), and to imipramine (IMI; 15 mg/kg/d), a reference antidepressant in this model. FSL rats displayed significantly reduced 5-HT (p = 0.03) and DA (p = 0.02) levels vs. FRL controls, while NA levels showed a similar trend. ORM-10921 significantly increased NA (all doses p ≤ 0.02), 5-HT (0.1 and 0.3 mg/kg p ≤ 0.03) and DA levels (all doses p ≤ 0.03), which correlated with decreased monoamine turnover. In contrast, IDAZ significantly elevated NA (p < 0.005) and DA (p < 0.004) but not 5-HT levels. IMI also significantly increased 5-HT (p < 0.009), with a tendency to increase NA (p = 0.09) but not DA. ORM-10921 exerts similar albeit broader effects on hippocampal monoamines than IDAZ, explaining earlier established efficacy associated with α-AR antagonism in animal models of depression and cognitive dysfunction. These and the current studies encourage application of ORM-10921 in depression in humans, as well as raise the intriguing possibility that selective α-AR antagonists may be beneficial in anxiety and stress-related disorders in companion animals. Both warrant further study.

Authors & Co-authors:  Harvey Brian H BH Uys Madeleine M MM Viljoen Francois P FP Shahid Mohammed M Sonntag Quixi Q Meyer Leith C R LCR

Study Outcome 

Source Link: Visit source

Statistics
Citations : 
Authors :  6
Identifiers
Doi : 10.1016/j.rvsc.2021.01.013
SSN : 1532-2661
Study Population
Male,Female
Mesh Terms
Adrenergic alpha-2 Receptor Antagonists
Other Terms
Antidepressant;Anxiety;Hippocampus;Major depression;Stress-related disorder;α2-adrenoreceptors
Study Design
Case Study,Cross Sectional Study
Study Approach
Country of Study
Publication Country
England